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Objective: A complete surgical resection is the cornerstone of therapy of thymic tumors. Unfortunately, there is
no standard treatment for pleural recurrence. This article describes our overall experience with the surgical treat-
ment of pleural implants in patients who previously underwent resection of a thymoma.
Material and Methods: From January 1980 to June 2006, 20 patients previously operated on for a thymoma
were operated on for the surgical resection of pleural implants. Patients with the initial Masaoka stage IVA
were excluded from our analysis. Our sample comprised 10 male and 10 female patients (12–65 years old).
The surgical approach to the resection of the thymoma was as follows: video-assissted thoracic surgery in 2
patients, sternotomy in 13 patients, thoracotomy in 2 patients, and sternothoracotomy in 3 patients. The initial
Masaoka stage of the thymoma was IIA in 2 patients, IIB in 7 patients, and III in 11 patients.
Results: The interval between resection of the thymoma and pleural implants ranged from 11 to 156 (median 60)
months. Fifteen patients had a thymus-related syndrome (in 13 patients it resulted myasthenia gravis), and in 11
patients it improved or remitted after treatment of the pleural recurrence. All the resections were performed
through a posterolateral thoracotomy. Three patients underwent an iterative resection of new pleural implants.
At the latest follow-up, 10 patients are still alive (8 disease-free) and 10 have died (9 of a relapse and 1 of the
complications of red cell aplasia). From the pleural recurrence resection, the overall 5- and 10-year survivals
are 43.1% and 25.8%, respectively.
Conclusions: Repeat operation on patients with thymoma pleural recurrences is feasible and safe. It can produce
satisfactory results in terms of overall survival and paraneoplastic syndrome control. Moreover, the multimodality
treatment could improve the results of surgical treatment.
Lucchi et al General Thoracic SurgeryThymomas are neoplasms arising from the epithelial thymic
cells. These tumors rarely metastasize distantly; on the
contrary, they can show pleural implants more frequently at
diagnosis or during follow-up.1 Data in the literature show
that pleural implants can also occur several years after the
resection of a thymoma, both encapsulated and invasive.2-7
Unfortunately, few reports have analyzed the treatment of
recurrences of thymoma,3-7 and few reports have focused
on pleural implants.8-10 The treatment of pleural implants is
controversial6,8,11-15; thus, the aims of our study were (1) to
retrospectively analyze our institutional experience on pleural
recurrences from thymoma and (2) to discuss the treatment
and prognosis of this highly selected group of patients.
PATIENTS AND METHODS
From January 1980 to June 2006, 20 of 257 patients undergoing resec-
tion for a stage I–III thymoma underwent the surgical resection of pleural
implants. Patients with initial Masaoka stage IVA were excluded from
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doi:10.1016/j.jtcvs.2008.09.033The Journal of Thoracic and Cour analysis. Collection of data and follow-up were done by reviewing med-
ical charts and by telephone contacts. Our samples (Table 1) consisted of 10
male and 10 female patients, and the ages of the patients at pleural implant
resection ranged from 12 to 65 years old. The surgical approach at the resec-
tion of the thymoma was video-assisted thoracic surgery (VATS) in 2 pa-
tients (recent patients, both operated on in another hospital), a sternotomy
in 13 (1 operated on in another institution), a thoracotomy in 2, and a sterno-
thoracotomy in 3. The initial Masaoka staging of the thymoma was IIA in 2
patients, IIB in 7 patients, and III in 11 patients. Six patients underwent neo-
adjuvant chemotherapy for an invasive stage III thymoma.
World Health Organization (WHO) histologic types of thymoma were
AB in 1 patient, B1 in 5 patients, B2 in 6 patients, and B3 in 8 patients. Post-
operative radiotherapy was offered to all patients of our series (since they all
had stage II or III thymomas). No patient underwent adjuvant chemotherapy
after resection of the thymoma. No neoadjuvant therapy was performed be-
fore the treatment of pleural implants. All patients were approached by a pos-
terolateral thoracotomy; in only 1 patient (previously treated by VATS) was
a sternothoracotomy performed. A partial pleurectomy was always per-
formed to resect the implants. On the other hand, a complete pleurec-
tomy/decortication (as for malignant pleural mesothelioma) was never
planned. In the case of a wide pleural spread or multiple implants, a small
intrapleural catheter was set at the end of the procedure and intrapleural che-
motherapy (epidoxorubicin 25 mg/m2) was administered on the fifth, sev-
enth, and ninth postoperative day. Since April 2005 (therefore, the last 3
patients), according to our latest in-house protocol, patients underwent hy-
perthermic intrapleural chemotherapy at 41C to 42C for 1 hour with cis-
platin and epidoxorubicin (Figure 1). When the diaphragm was involved,
we always performed a partial resection, suturing the break with nonabsorb-
able single stitches (Figure 2).
We used adjuvant chemotherapy with the scheduling of cisplatin–
epidoxorubicin–etoposide or carboplatinum–taxol (according to the perfor-
mance status of the patient) when pleural disease was massive and resection
should be considered cytoreductive and not radical.ardiovascular Surgery c Volume 137, Number 5 1185




VATS ¼ video-assisted thoracic surgery
WHO ¼ World Health Organization
Since November 2000 (last 6 patients) all patients have undergone long-
term therapy (6–24 months) with a slow-release octreotide.
The study was approved by our hospital review board.
The statistical analysis was performed by the STATISTICA software
(StatSoft, Inc, Tulsa, Okla). Univariable analysis by the Mann–Whitney
U test for continuous variables and the c2 test for discrete variables were
used to assess differences of tumor characteristics between patients who
had a relapse and those who had not. Survival curves were estimated by
the Kaplan–Meier product limit method and were compared by the log–
rank test.
RESULTS
The incidence of pleural recurrences in our population of
resected thymoma (excluding the stage IVA thymomas and
the patients operated on in another hospital) is 6.6%. The
median interval between the resection of the thymoma and
the pleural implants was 60 months (range 11–156). At the
diagnosis of pleural relapse, 15 patients had a thymus-re-
lated syndrome (in 13 patients, myasthenia gravis). In all pa-
tients it was present at resection of the thymoma, but in 8
patients, after a period of improvement or complete remis-
sion, the symptoms worsened. In 9 patients the pleural im-
plants were single whereas in 11 they were multiple.
Visceral and parietal pleural disseminated lesions were re-
sected with small margins. Intercostal or pulmonary paren-
chymal involvement was managed with chest wall
resection (n ¼ 2) or wedge resections of the involved lung
(n ¼ 8). In 7 patients the pleural implants involved the dia-
phragm and required a partial resection of the diaphragm.
Our mortality rate was nil. The mean hospital stay was
10.2 days (range 6–22 days). As regards postoperative mor-
bidity, there was one episode of bleeding (necessitating a re-
operation on the second postoperative day), and there were
two prolonged air leaks. Three patients underwent iterative
resections of pleural implants (2 patients underwent a second
resection and 1 patient a third). The resection was macro-
scopically radical in 13 patients and therefore adiuvant che-
motherapy was administered only to 7 patients.
With a median follow-up of 98 months (range 13–301),
10 patients are still alive. Eight patients are radiologically
disease free, 4 had a local relapse, 5 a systemic relapse,
and 2 both a local and systemic relapse. One patient (disease
free) died of the complications of red cell aplasia.
The outcomes of the thymus-related syndrome after the
treatment of pleural recurrences from thymoma were as fol-
lows: 5 patients had a remission, 6 improved, 3 remained in
stable condition, and only 1 worsened.
The 10- and 20-year actuarial survivals from the resection
of the thymoma were 66% and 34.3%, respectively. The1186 The Journal of Thoracic and Cardiovascular Su5- and 10-year actuarial survivals from the pleural recur-
rence resection were 43.1% and 25.8%, respectively (Fig-
ure 3). Even though most of the initial thymomas were
stage III and B3, neither the Masaoka staging nor the
WHO histologic classification significantly affected the sur-
vival calculated from the resection of the pleural relapse. The
comparison of the survivals according to the disease-free
interval (<vs>60 months) did not reach statistical signifi-
cance.
Comparing the survival of single versus multiple im-
plants, we found that the difference was statistically signifi-
cant (P ¼ .03) (Figure 4). Patients with diaphragmatic
involvement showed a significantly worse prognosis (P ¼
.01) (Figure 5).
DISCUSSION
If thymoma is rare, pleural recurrences are even rarer; they
account for less than 10% of resected thymomas.1-5
Only a few case reports focused on the surgical treatment
of pleural implants that were discovered at follow-up,13
whereas most of the articles reported pleural recurrences
from thymoma together with mediastinal and systemic re-
lapses. The etiology of the appearance of pleural implants
many years after resection of a noninvasive thymoma is
not clear. They may have been present at the time of thy-
moma resection or they may be due to the seeding of tumoral
cells during the manipulation of the tumor, especially if the
mediastinal pleura has been opened. In our experience, we
have always tried to avoid opening the mediastinal pleura
in case the thymoma was not invasive. Moreover, we have
never performed a thoracoscopy to exclude the presence of
pleural disease if the preoperative computed tomographic
scan was negative for pleural effusion or implants. On the
other hand, we found 2 cases of thymoma (1 stage IIB and
1 stage III) resected by VATS in different hospitals. These
patients had a pleural relapse at 38 and 13 months,
TABLE 1. Patient characteristics
Patients’s characteristics No.
Sex (M vs F) 10 vs 10
Age (y) 45.8 (range, 12-65)









Interval (mo) 60 (range, 11-156)
Thymus-related syndrome (yes vs no) 15 vs 5
No. of implants (single vs multiple) 9 vs 11
Diaphragmatic implants (yes vs no) 7 vs 13rgery c May 2009
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SFIGURE 1. A single pleural implant in the left vertebral douche. A, Computed tomography. B, Operative view. After the resection, intrapleural hyperthermic
chemotherapy was applied. C, The machine. D, Operative view before starting perfusion.respectively. This event could stimulate a discussion about
the benefit of resecting the thymomas using VATS or robotic
technology and the possibility that minimally invasive tech-
niques could expose the patients to a higher risk of pleural
relapse.
With regard to the surgical treatment of relapses from
thymoma, the articles by Ruffini,3 Regnard,5 and their
associates still remain significant with their overall 30 and
FIGURE 2. Resection of a left diaphragmatic implant.The Journal of Thoracic and C28 cases, respectively. Both groups of authors concluded
that surgical resection is recommended and a poor prognosis
can be predicted by the presence of distant recurrences. As
a matter of fact, there is no scientific evidence that surgical
treatment is superior to other treatments, because in all
published studies3,5,6 surgery was reserved to resectable
recurrent tumors in patients with good clinical conditions;
undoubtedly, this is an important clinical selection bias.
FIGURE 3. Five- and 10-year overall survival calculated from the pleural
recurrence resection.ardiovascular Surgery c Volume 137, Number 5 1187
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usually a matter of local control. For this reason, the report
recently published by Wright15 about pleuropneumonec-
tomy for the management of selected cases of stage IVA
thymoma or pleural relapse was very provocative. The hy-
pothesis that pleuropneumonectomy, a procedure usually re-
served for malignant pleural mesothelioma, could be useful
above all for thymoma is supported by the positive prognos-
tic value of radical surgery in this slowly evolving disease.
Wright treated 5 patients, 2 of whom had massive pleural re-
currences from B3 thymomas. He concluded that the proce-
dure is safe and should be part of a multimodality strategy.
Similar to the treatment of malignant pleural mesotheli-
oma, some authors8,13 have added hyperthermic intrapleural
chemotherapy to the surgical resection of pleural recurrences
from thymoma. In our last 3 patients we also used hyperther-
mic intraoperative administration of 2 drugs (cisplatin and
epidoxorubicin); the outcome is still ‘‘in progress,’’ but
the treatment is feasible with low morbidity.
Thymomas are very sensitive to radiation,16 but adjuvant
radiotherapy after thymoma resection does not decrease the
incidence of pleural relapses inasmuch as the implants are
set out of the radiation field.
Low-dose entire hemithorax radiotherapy for pleural dis-
semination or relapse has been described in only a few arti-
cles,9,17,18 which showed that this method is safe and could
contribute to the control of pleural dissemination.
Advanced and recurrent thymomas are also responsive to
systemic chemotherapy, as reported by Giaccone and asso-
ciates,12 who found a 31% response rate to chemotherapy.
To decrease the toxicity of systemic chemotherapy and
also to achieve better local control, Terada and colleagues13
have successfully managed 2 cases of pleural recurrences by
transarterial infusion of chemotherapy through the intercos-
tal arteries and subphrenic artery.
FIGURE 4. Overall survival according to the number of implants (single
versus multiple).1188 The Journal of Thoracic and Cardiovascular SuWhen the resection was not radical, we also decided to use
adjuvant chemotherapy. Unfortunately, the literature con-
tains no supportable evidence of its value.
The last 6 patients received additional adjuvant predni-
sone and octreotide according to the preliminary experience
of Palmieri and coworkers19 and the Eastern Cooperative
Oncology phase II trial by Loehrer and associates,20 who ob-
tained outstanding results in advanced-stage thymomas.
Even if our series are small and the period of analysis is
long, we have found some interesting results. Among the an-
alyzed variables, only diaphragmatic involvement and num-
ber of implants were statistically significant, with a worse
prognosis in patients with diaphragmatic and multiple im-
plants. A possible explanation is that multiple implants,
those particularly involving the diaphragm, express a more
advanced disease. This issue and the data in the literature,
showing that the mean disease-free period is between 60
and 80 months, stress the role of lifetime follow-up to detect
recurrences of thymoma at an early stage.
The WHO’s histologic classification system reflects the
oncologic behavior of thymoma,21-23 with most pleural re-
currences occurring in type B3 thymoma. On the other
hand, the WHO’s histologic classification system is not
a prognostic indicator when the survival is calculated from
the occurrence of pleural relapse itself.
We avoided performing multivariable analysis, which is
not meaningful with so few patients.
After surgical resection, a subsequent pleural recurrence
is probable, so that a strict radiologic follow-up is mandatory
in this subset of patients. When a new pleural relapse is
found, an iterative resection should be considered.24 We
have performed 3 iterative resections of pleural implants
and in 1 case a third operation was performed; all the patients
were long-term survivors and 2 of them are still alive and
well.
FIGURE 5. Overall survival according to the diaphragmatic involvement.rgery c May 2009
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recurrences is feasible and safe. The next question is an
open one: Which kind of operation should be performed
in the case of a pleural relapse from thymoma—simple re-
section of the implant, complete pleurectomy, or an extrap-
leural pneumonectomy? A conclusive answer is not
possible and the choice is still based on the status of the
disease, on the status of the patient, and on the policy of
the surgeon.
The take-home message is this: Do not give up in this
indolent disease. Always consider a reresection, because
everything else is based on speculation and theory.
We thank Dr. Jennifer Johnson and Mrs. Paola Moretti, for their
assistance in manuscript preparation.
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